View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Carvana Co: 3 directors

Three Directors at Carvana Co sold after exercising options/sold 23,750 shares at between 393.040USD and 411.274USD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 31, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 29, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

NBT Bancorp Inc. Announces Full Year 2025 Results and Declares Cash Di...

NBT Bancorp Inc. Announces Full Year 2025 Results and Declares Cash Dividend NORWICH, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) reported net income and diluted earnings per share for the three and twelve months ended December 31, 2025. Net income for the fourth quarter of 2025 was $55.5 million, or $1.06 per diluted common share, compared to $36.0 million, or $0.76 per diluted common share, for the fourth quarter of 2024, and $54.5 million, or $1.03 per diluted common share, for the third quarter of 2025. Operating diluted earnings p...

 PRESS RELEASE

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scie...

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company present...

Huntington Bancshares Incorporated: Update to credit analysis followin...

Our credit view of this issuer reflects its diversified loan portfolio and good earnings profile, as well as integration and execution risk related to recent M&A activity.

 PRESS RELEASE

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan ...

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. Dr Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBe...

Moody's Ratings affirms Huntington's ratings (long-term senior unsecur...

Moody's Ratings (Moody's) has today affirmed the ratings and assessments of Huntington Bancshares Incorporated and its lead bank, Huntington National Bank (The) (collectively referred to as "Huntington"), including Huntington Bancshares Incorporated's Baa1 long-term local currency senior unsecured r...

 PRESS RELEASE

NBT Bancorp Inc. Announces Date of Fourth Quarter Conference Call

NBT Bancorp Inc. Announces Date of Fourth Quarter Conference Call NORWICH, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) will release details of its financial results for the fourth quarter 2025 on Monday, January 26, 2026, following the market close. The Company will host a conference call at 10:00 a.m. (Eastern) Tuesday, January 27, 2026, to review these results. The audio webcast link, along with the corresponding presentation slides, will be available on the Company’s Event Calendar page at prior to the beginning of the conference c...

 PRESS RELEASE

AtaiBeckley Completes Redomiciliation to the United States

AtaiBeckley Completes Redomiciliation to the United States NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company’s extra...

 PRESS RELEASE

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. “2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pip...

 PRESS RELEASE

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA fo...

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem...

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Tough Road Ahead; Neutral, $36 PT

Figure 1. 3QFY26 Results vs. EstimatesSource: Company reports, Wedbush estimates, FactSet consensusCarMax reported results mostly in-line with lowered expectations for 3Q. In the quarter, the company reported revenue of $5.8B (-6.9% Y/Y), ~3% ahead of St. expectations of $5.6B (-9.9% Y/Y). 3Q retai

 PRESS RELEASE

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthenin...

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term...

Sensient Technologies Corp: 1 director

A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Nkarta to Participate in Evercore Healthcare Conference

Nkarta to Participate in Evercore Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the of Nkarta’s website, and a replay will be archived on the web...

 PRESS RELEASE

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rul...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on November 3, 2025, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch